Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Phylodynamic analysis of HIV-1 subtypes B, C and CRF 02_AG in Senegal.

Nascimento FF, Baral S, Geidelberg L, Mukandavire C, Schwartz SR, Turpin G, Turpin N, Diouf D, Diouf NL, Coly K, Kane CT, Ndour C, Vickerman P, Boily MC, Volz EM.

Epidemics. 2019 Nov 14:100376. doi: 10.1016/j.epidem.2019.100376. [Epub ahead of print]

2.

Human Papillomavirus infection in senegalese female sex workers.

Diop-Ndiaye H, Beiter K, Gheit T, Sow Ndoye A, Dramé A, McKay-Chopin S, Tommasino M, Bouh Boye CS, Sylla B, Kane CT.

Papillomavirus Res. 2019 Jun;7:97-101. doi: 10.1016/j.pvr.2019.02.003. Epub 2019 Feb 13.

3.

Surveillance of transmitted HIV-1 antiretroviral drug resistance in the context of decentralized HIV care in Senegal and the Ebola outbreak in Guinea.

Mbange AE, Kaba D, Diouara AAM, Diop-Ndiaye H, Ngom-Ngueye NF, Dieng A, Lo S, Toure KN, Fall M, Mbacham WF, Diallo MS, Cisse M, Mboup S, Kane CT.

BMC Res Notes. 2018 Oct 12;11(1):723. doi: 10.1186/s13104-018-3804-9.

4.

Estimating the contribution of key populations towards the spread of HIV in Dakar, Senegal.

Mukandavire C, Walker J, Schwartz S, Boily MC, Danon L, Lyons C, Diouf D, Liestman B, Diouf NL, Drame F, Coly K, Muhire RSM, Thiam S, Diallo PAN, Kane CT, Ndour C, Volz E, Mishra S, Baral S, Vickerman P.

J Int AIDS Soc. 2018 Jul;21 Suppl 5:e25126. doi: 10.1002/jia2.25126.

5.

Characterization of potent and selective iodonium-class inhibitors of NADPH oxidases.

Lu J, Risbood P, Kane CT Jr, Hossain MT, Anderson L, Hill K, Monks A, Wu Y, Antony S, Juhasz A, Liu H, Jiang G, Harris E, Roy K, Meitzler JL, Konaté M, Doroshow JH.

Biochem Pharmacol. 2017 Nov 1;143:25-38. doi: 10.1016/j.bcp.2017.07.007. Epub 2017 Jul 11.

6.

Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.

Ciaffi L, Koulla-Shiro S, Sawadogo AB, Ndour CT, Eymard-Duvernay S, Mbouyap PR, Ayangma L, Zoungrana J, Gueye NFN, Diallo M, Izard S, Bado G, Kane CT, Aghokeng AF, Peeters M, Girard PM, Le Moing V, Reynes J, Delaporte E; MOBIDIP study group.

Lancet HIV. 2017 Sep;4(9):e384-e392. doi: 10.1016/S2352-3018(17)30069-3. Epub 2017 May 28.

PMID:
28566227
7.

Ending AIDS as a public health threat by 2030: Scientific Developments from the 2016 INTEREST Conference in Yaoundé, Cameroon.

Hankins CA, Koulla-Shiro S, Kilmarx P, Ferrari G, Schechter M, Kane CT, Venter F, Boucher CA, Ross AL, Zewdie D, Eholié SP, Katabira E.

Antivir Ther. 2017;22(2):179-184. doi: 10.3851/IMP3165. Epub 2017 Apr 7.

8.

Implementation of an in-house quantitative real-time polymerase chain reaction method for Hepatitis B virus quantification in West African countries.

Ghosh S, Sow A, Guillot C, Jeng A, Ndow G, Njie R, Toure S, Diop M, Mboup S, Kane CT, Lemoine M, Thursz M, Zoulim F, Mendy M, Chemin I.

J Viral Hepat. 2016 Nov;23(11):897-904. doi: 10.1111/jvh.12561. Epub 2016 Jun 29.

PMID:
27353593
9.

Pitfalls of antiretroviral drug resistance genotyping of HIV-1 Group M and Group N from Cameroon by sequenced-based assays.

Jenabian MA, Talla F, Talla P, Mbopi-Kéou FX, Charpentier C, Kane CT, Bélec L.

Niger Med J. 2015 Nov-Dec;56(6):420-4. doi: 10.4103/0300-1652.171613.

10.

Usefulness of Dried Blood Spots (DBS) to perform hepatitis C virus genotyping in drug users in Senegal.

Ndiaye O, Gozlan J, Diop-Ndiaye H, Sall AS, Chapelain S, Leprêtre A, Maynart M, Gueye M, Lo G, Thiam M, Ba I, Lacombe K, Girard PM, Mboup S, Kane CT.

J Med Virol. 2017 Mar;89(3):484-488. doi: 10.1002/jmv.24460. Epub 2016 Nov 9.

PMID:
26705258
11.

Prevalence and behavioural risks for HIV and HCV infections in a population of drug users of Dakar, Senegal: the ANRS 12243 UDSEN study.

Leprêtre A, Ba I, Lacombe K, Maynart M, Toufik A, Ndiaye O, Kane CT, Gozlan J, Tine J, Ndoye I, Raguin G, Girard PM.

J Int AIDS Soc. 2015 May 22;18:19888. doi: 10.7448/IAS.18.1.19888. eCollection 2015.

12.

LETTER TO THE EDITOR Performance of the ViroSeq® HIV-1 Genotyping System v2.0 in Central Africa.

Mouafo LC, Péré H, Ndjoyi-Mbiguino A, Koyalta D, Longo Jde D, Mbopi-Kéou FX, Kane CT, Bélec L.

Open AIDS J. 2015 Feb 27;9:9-13. doi: 10.2174/1874613601509010009. eCollection 2015.

13.

Dried blood spots for HIV-1 drug resistance genotyping in decentralized settings in Senegal.

Diouara AA, Diop-Ndiaye H, Kebe-Fall K, Tchiakpè E, Ndiaye O, Ayouba A, Peeters M, Mboup S, Kane CT.

J Med Virol. 2014 Jan;86(1):45-51. doi: 10.1002/jmv.23778. Epub 2013 Oct 1.

PMID:
24122937
14.

RNA versus DNA (NucliSENS EasyQ HIV-1 v1.2 versus Amplicor HIV-1 DNA test v1.5) for early diagnosis of HIV-1 infection in infants in Senegal.

Kébé K, Ndiaye O, Ndiaye HD, Mengue PM, Guindo PM, Diallo S, Léye N, Gueye SB, Diallo AG, Kane CT, Mboup S.

J Clin Microbiol. 2011 Jul;49(7):2590-3. doi: 10.1128/JCM.02402-10. Epub 2011 May 4.

15.

Changes in the renal function after tenofovir-containing antiretroviral therapy initiation in a Senegalese cohort (ANRS 1215).

De Beaudrap P, Diallo MB, Landman R, Guèye NF, Ndiaye I, Diouf A, Kane CT, Etard JF, Girard PM, Sow PS, Delaporte E; ANRS 1215 Study Group.

AIDS Res Hum Retroviruses. 2010 Nov;26(11):1221-7. doi: 10.1089/aid.2009.0261. Epub 2010 Sep 21.

PMID:
20854202
16.

Efficacy and safety of unboosted atazanavir in combination with lamivudine and didanosine in naive HIV type 1 patients in Senegal.

Landman R, Diallo MB, Gueye NF, Kane CT, Mboup S, Fall MB, Ndiaye B, Peytavin G, Bennai Y, Benalycherif A, Girard PM, Sow PS.

AIDS Res Hum Retroviruses. 2010 May;26(5):519-25. doi: 10.1089/aid.2009.0123.

PMID:
20455760
17.

Low prevalence of HIV type 1 drug resistance mutations in untreated, recently infected patients from Burkina Faso, Côte d'Ivoire, Senegal, Thailand, and Vietnam: the ANRS 12134 study.

Ayouba A, Lien TT, Nouhin J, Vergne L, Aghokeng AF, Ngo-Giang-Huong N, Diop H, Kane CT, Valéa D, Rouet F, Joulia-Ekaza D, Toni TD, Nerrienet E, Ngole EM, Delaporte E, Costagliola D, Peeters M, Chaix ML.

AIDS Res Hum Retroviruses. 2009 Nov;25(11):1193-6. doi: 10.1089/aid.2009.0142.

PMID:
19886834
18.

Concentrated and linked epidemics of both HSV-2 and HIV-1/HIV-2 infections in Senegal: public health impacts of the spread of HIV.

Kane CT, Diawara S, Ndiaye HD, Diallo PA, Wade AS, Diallo AG, Belec L, Mboup S.

Int J STD AIDS. 2009 Nov;20(11):793-6. doi: 10.1258/ijsa.2008.008414.

PMID:
19875833
19.

Synthesis of gemcitabine triphosphate (dFdCTP) as a tris(triethylammonium) salt.

Risbood PA, Kane CT Jr, Hossain MT, Vadapalli S, Chadda SK.

Bioorg Med Chem Lett. 2008 May 1;18(9):2957-8. doi: 10.1016/j.bmcl.2008.03.063. Epub 2008 Mar 25.

20.

Poor efficacy and tolerability of stavudine, didanosine, and efavirenz-based regimen in treatment-naive patients in Senegal.

Canestri A, Sow PS, Vray M, Ngom F, M'boup S, Kane CT, Delaporte E, Gueye M, Peytavin G, Girard PM, Landman R; ANRS 12-06/IMEA 012 Trial Study Group.

MedGenMed. 2007 Oct 9;9(4):7.

21.

Quantitation of HIV-1 RNA in dried blood spots by the real-time NucliSENS EasyQ HIV-1 assay in Senegal.

Kane CT, Ndiaye HD, Diallo S, Ndiaye I, Wade AS, Diaw PA, Gaye-Diallo A, Mboup S.

J Virol Methods. 2008 Mar;148(1-2):291-5. doi: 10.1016/j.jviromet.2007.11.011. Epub 2008 Feb 1.

PMID:
18242718
22.

A bifunctional colchicinoid that binds to the androgen receptor.

Sharifi N, Hamel E, Lill MA, Risbood P, Kane CT Jr, Hossain MT, Jones A, Dalton JT, Farrar WL.

Mol Cancer Ther. 2007 Aug;6(8):2328-36.

23.

Poor Efficacy and Tolerability of Stavudine, Didanosine, and Efavirenz-based Regimen in Treatment-Naive Patients in Senegal.

Canestri A, Sow PS, Vray M, Ngom F, M'boup S, Kane CT, Delaporte E, Gueye M, Peytavin G, Girard PM, Landman R; ANRS 12-06/IMEA 012 Trial Study Group.

J Int AIDS Soc. 2007 Oct 9;9(4):7. doi: 10.1186/1758-2652-9-4-7.

24.

HIV infection and sexually transmitted infections among men who have sex with men in Senegal.

Wade AS, Kane CT, Diallo PA, Diop AK, Gueye K, Mboup S, Ndoye I, Lagarde E.

AIDS. 2005 Dec 2;19(18):2133-40.

PMID:
16284463
25.

Low rate of genotypic HIV-1 drug-resistant strains in the Senegalese government initiative of access to antiretroviral therapy.

Vergne L, Kane CT, Laurent C, Diakhaté N, Gueye NF, Gueye PM, Sow PS, Faye MA, Liégeois F, Ndir A, Lanièce I, Peeters M, Ndoye I, Mboup S, Delaporte E.

AIDS. 2003 Jul;17 Suppl 3:S31-8.

PMID:
14565607
26.

Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal.

Landman R, Schiemann R, Thiam S, Vray M, Canestri A, Mboup S, Kane CT, Delaporte E, Sow PS, Faye MA, Gueye M, Peytavin G, Dalban C, Girard PM, Ndoye I; Imea 011/ANRS 12-04 Study Group.

AIDS. 2003 May 2;17(7):1017-22.

PMID:
12700451
27.

No difference in clinical progression between patients infected with the predominant human immunodeficiency virus type 1 circulating recombinant form (CRF) 02_AG strain and patients not infected with CRF02_AG, in Western and West-Central Africa: a four-year prospective multicenter study.

Laurent C, Bourgeois A, Faye MA, Mougnutou R, Seydi M, Gueye M, Liégeois F, Kane CT, Butel C, Mbuagbaw J, Zekeng L, Mboup S, Mpoudi-Ngolé E, Peeters M, Delaporte E.

J Infect Dis. 2002 Aug 15;186(4):486-92. Epub 2002 Jul 19.

PMID:
12195375
28.

Synthesis of biotin conjugates of the antifungal compound cymoxanil.

Evans KA, Kane CT, Tice CM.

Pest Manag Sci. 2002 Apr;58(4):392-6.

PMID:
11975188
29.

Full-length genome sequencing of HIV type 1 group O viruses isolated from a heterosexual transmission cluster in Senegal.

Kane CT, Montavon C, Toure MA, Faye MA, Ndiaye AG, Diallo AG, Ndoye I, Liegeois F, Delaporte E, Mboup S, Peeters M.

AIDS Res Hum Retroviruses. 2001 Aug 10;17(12):1211-6.

PMID:
11522190
30.

Evaluation of phosphoramidon and three synthetic phosphonates for inhibition of botulinum neurotoxin B catalytic activity.

Adler M, Nicholson JD, Starks DF, Kane CT, Cornille F, Hackley BE Jr.

J Appl Toxicol. 1999 Dec;19 Suppl 1:S5-S11.

PMID:
10594892
31.

A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal.

Simondon F, Preziosi MP, Yam A, Kane CT, Chabirand L, Iteman I, Sanden G, Mboup S, Hoffenbach A, Knudsen K, Guiso N, Wassilak S, Cadoz M.

Vaccine. 1997 Oct;15(15):1606-12.

PMID:
9364690
32.

Viability of Bordetella pertussis in four suspending solutions at three temperatures.

Cassiday PK, Sanden GN, Kane CT, M'Boup S, Barbaree JM.

J Clin Microbiol. 1994 Jun;32(6):1550-3.

33.

Terpenoid biosynthesis and the stereochemistry of enzyme-catalysed allylic addition-elimination reactions.

Cane DE, Abell C, Harrison PH, Hubbard BR, Kane CT, Lattman R, Oliver JS, Weiner SW.

Philos Trans R Soc Lond B Biol Sci. 1991 May 29;332(1263):123-9.

PMID:
1678531

Supplemental Content

Support Center